Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,514.19
(
-1.18%
)
US TECH 100
23,123.60
(
-1.66%
)
Dow Jones
46,050.26
(
-0.82%
)
Brent Oil
102.67
(
3.94%
)
Bitcoin
69,095.64
(
-3.10%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122813
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Bickema post# 202517

Monday, 07/11/2016 12:19:33 PM

Monday, July 11, 2016 12:19:33 PM

Post# of 257293
EGRX—Next cycle FDA approval for Kangio in this context means that I expect EGRX will resubmit the 505b2 NDA (without new clinical trials) and will get FDA approval based on the review of the resubmitted NDA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today